DENTSPLY SIRONA Inc. (NASDAQ:XRAY) had its price target lifted by analysts at Morgan Stanley from $66.00 to $67.00 in a research note issued to investors on Thursday. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. Morgan Stanley’s price objective indicates a potential upside of 20.72% from the stock’s current price.

A number of other equities analysts have also recently commented on XRAY. Zacks Investment Research upgraded DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a report on Wednesday, April 12th. Goldman Sachs Group, Inc. (The) cut DENTSPLY SIRONA from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $60.00 to $55.00 in a report on Tuesday, May 23rd. Cleveland Research upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating in a report on Tuesday, May 23rd. BidaskClub cut DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. Finally, HC Wainwright initiated coverage on DENTSPLY SIRONA in a report on Tuesday, July 11th. They issued a “buy” rating and a $74.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. DENTSPLY SIRONA currently has a consensus rating of “Buy” and a consensus price target of $67.42.

DENTSPLY SIRONA (NASDAQ XRAY) traded down 1.30% during mid-day trading on Thursday, hitting $55.50. The stock had a trading volume of 3,519,311 shares. DENTSPLY SIRONA has a 12 month low of $55.00 and a 12 month high of $65.68. The stock has a market cap of $12.72 billion, a price-to-earnings ratio of 35.71 and a beta of 1.26. The stock’s 50-day moving average price is $63.39 and its 200-day moving average price is $62.35.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.65. The firm had revenue of $992.70 million during the quarter, compared to analysts’ expectations of $1 billion. DENTSPLY SIRONA had a return on equity of 7.37% and a net margin of 9.42%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.76 EPS. On average, analysts predict that DENTSPLY SIRONA will post $2.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Price Target Raised to $67.00 at Morgan Stanley” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/10/dentsply-sirona-inc-nasdaqxray-price-target-raised-to-67-00-at-morgan-stanley.html.

Institutional investors have recently bought and sold shares of the stock. Retirement Systems of Alabama boosted its position in DENTSPLY SIRONA by 1.5% in the first quarter. Retirement Systems of Alabama now owns 111,024 shares of the medical instruments supplier’s stock worth $6,932,000 after buying an additional 1,595 shares during the last quarter. State of Alaska Department of Revenue boosted its position in DENTSPLY SIRONA by 58.2% in the first quarter. State of Alaska Department of Revenue now owns 19,188 shares of the medical instruments supplier’s stock worth $1,197,000 after buying an additional 7,062 shares during the last quarter. Farmers & Merchants Investments Inc. boosted its position in DENTSPLY SIRONA by 3.6% in the first quarter. Farmers & Merchants Investments Inc. now owns 94,521 shares of the medical instruments supplier’s stock worth $5,902,000 after buying an additional 3,300 shares during the last quarter. Howland Capital Management LLC acquired a new position in DENTSPLY SIRONA during the first quarter worth about $203,000. Finally, Mountain Pacific Investment Advisers Inc. ID boosted its position in DENTSPLY SIRONA by 2.0% in the first quarter. Mountain Pacific Investment Advisers Inc. ID now owns 386,371 shares of the medical instruments supplier’s stock worth $24,125,000 after buying an additional 7,710 shares during the last quarter. Institutional investors own 95.17% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.